Heffernan Michael Thomas — SEC Form 4 filings
SEC reporting owner CIK 1448914. 14 Form 4 filings on record with FilingPulse; latest filed 2026-09-17.
Transaction summary — filings shown
Covers all 14 filings on record, filed 2024-05-02 to 2026-09-17. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 4 legs across 1 filing — 39,473 shares, $595,806 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 17.
- Largest priced transaction: sale of 20,952 shares @ $15.09 ($316,166) in Trevi Therapeutics, Inc., filed 2026-09-17.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Trevi Therapeutics, Inc. (TRVI) | Director | 4 | — | 4 legs · 39,473 sh · $595,806 | 7 |
| Avalo Therapeutics, Inc. (AVTX) | Director | 3 | — | — | 3 |
| Biohaven Ltd. (BHVN) | Director | 3 | — | — | 3 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | Director | 2 | — | — | 2 |
| enGene Therapeutics Inc. (ENGN) | Director | 2 | — | — | 2 |
Form 4 filings — Heffernan Michael Thomas
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-17 | 4 | Trevi Therapeutics, Inc. (TRVI) | Option exercise (M): 18,421 @ $3.04 · Sale (S): 18,321 @ $15.09 · Sale (S): 100 @ $15.88 · Option exercise (M): 21,052 @ $3.33 · Sale (S): 20,952 @ $15.09 · Sale (S): 100 @ $15.88 · +2 more | EDGAR |
| 2026-06-17 | 4 | enGene Therapeutics Inc. (ENGN) | Grant/award (A): 31,000 (derivative) @ $0 | EDGAR |
| 2026-06-04 | 4 | Trevi Therapeutics, Inc. (TRVI) | Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2026-06-04 | 4 | Avalo Therapeutics, Inc. (AVTX) | Grant/award (A): 29,500 (derivative) @ $0 | EDGAR |
| 2026-04-30 | 4 | Biohaven Ltd. (BHVN) | Grant/award (A): 68,693 (derivative) @ $0 | EDGAR |
| 2025-07-10 | 4 | enGene Holdings Inc. (ENGN) | Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
| 2025-06-18 | 4 | Avalo Therapeutics, Inc. (AVTX) | Grant/award (A): 29,500 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | Trevi Therapeutics, Inc. (TRVI) | Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
| 2025-05-07 | 4 | Biohaven Ltd. (BHVN) | Grant/award (A): 31,716 (derivative) @ $0 | EDGAR |
| 2025-03-26 | 4 | Avalo Therapeutics, Inc. (AVTX) | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2025-02-12 | 4 | COLLEGIUM PHARMACEUTICAL, INC (COLL) | Grant/award (A): 4,820 @ $0 | EDGAR |
| 2024-06-14 | 4 | Trevi Therapeutics, Inc. (TRVI) | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2024-05-16 | 4 | COLLEGIUM PHARMACEUTICAL, INC (COLL) | Grant/award (A): 7,693 @ $0 | EDGAR |
| 2024-05-02 | 4 | Biohaven Ltd. (BHVN) | Grant/award (A): 16,592 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1448914 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →